Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas: A single centre experience

Silvia Uccella, Claudia Placidi, Silvia Marchet, Massimiliano Cergnul, Ilaria Proserpio, Claudio Chini, Raffaele Novario, Graziella Pinotti, Carlo Capella

Research output: Contribution to journalArticle

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. The immunohistochemistry-based algorithms for the determination of the cell of origin of DLBCL have been proposed as a practical method to validate and surrogate results obtained by gene expression profiling. We studied 71 patients with primary nodal DLBCL at diagnosis, who received anthracycline-based therapy with or without rituximab. Immunohistochemistry was performed using anti-CD10, Bcl-6, MUM1 and Bcl-2 antibodies in order to assess the ontogenic profile of neoplastic cells and to verify its relation with clinical outcome. Survival data were analysed using an explorative Cox model. The immunohistochemistry-based algorithms for the determination of the cell of origin of DLBCL were not associated with prognosis. By contrast, Bcl-6 expression was associated with a longer lymphoma-free survival while immunoreactivities for MUM1 or Bcl-2 were not significantly related to patient outcome. Bcl-6 expression alone proved to be a prognostic marker in primary nodal DLBCL and seemed to be more reliable to predict clinical outcome in these disorders than the immunohistochemical algorithms for the detection of the germinal centre/non-germinal centre immunophenotype.

Original languageEnglish
Pages (from-to)1321-1328
Number of pages8
JournalLeukemia and Lymphoma
Volume49
Issue number7
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Germinal Center
Lymphoma, Large B-Cell, Diffuse
Immunohistochemistry
Proteins
Survival
Anthracyclines
Gene Expression Profiling
Proportional Hazards Models
Lymphoma
Antibodies

Keywords

  • Bcl-6
  • CD10
  • Diffuse large B-cell lymphoma
  • Germinal centre phenotype
  • Immunohistochemistry

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas : A single centre experience. / Uccella, Silvia; Placidi, Claudia; Marchet, Silvia; Cergnul, Massimiliano; Proserpio, Ilaria; Chini, Claudio; Novario, Raffaele; Pinotti, Graziella; Capella, Carlo.

In: Leukemia and Lymphoma, Vol. 49, No. 7, 07.2008, p. 1321-1328.

Research output: Contribution to journalArticle

Uccella, Silvia ; Placidi, Claudia ; Marchet, Silvia ; Cergnul, Massimiliano ; Proserpio, Ilaria ; Chini, Claudio ; Novario, Raffaele ; Pinotti, Graziella ; Capella, Carlo. / Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas : A single centre experience. In: Leukemia and Lymphoma. 2008 ; Vol. 49, No. 7. pp. 1321-1328.
@article{b5caf7f5c38549d19dababbf4e7491c3,
title = "Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas: A single centre experience",
abstract = "Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. The immunohistochemistry-based algorithms for the determination of the cell of origin of DLBCL have been proposed as a practical method to validate and surrogate results obtained by gene expression profiling. We studied 71 patients with primary nodal DLBCL at diagnosis, who received anthracycline-based therapy with or without rituximab. Immunohistochemistry was performed using anti-CD10, Bcl-6, MUM1 and Bcl-2 antibodies in order to assess the ontogenic profile of neoplastic cells and to verify its relation with clinical outcome. Survival data were analysed using an explorative Cox model. The immunohistochemistry-based algorithms for the determination of the cell of origin of DLBCL were not associated with prognosis. By contrast, Bcl-6 expression was associated with a longer lymphoma-free survival while immunoreactivities for MUM1 or Bcl-2 were not significantly related to patient outcome. Bcl-6 expression alone proved to be a prognostic marker in primary nodal DLBCL and seemed to be more reliable to predict clinical outcome in these disorders than the immunohistochemical algorithms for the detection of the germinal centre/non-germinal centre immunophenotype.",
keywords = "Bcl-6, CD10, Diffuse large B-cell lymphoma, Germinal centre phenotype, Immunohistochemistry",
author = "Silvia Uccella and Claudia Placidi and Silvia Marchet and Massimiliano Cergnul and Ilaria Proserpio and Claudio Chini and Raffaele Novario and Graziella Pinotti and Carlo Capella",
year = "2008",
month = "7",
doi = "10.1080/10428190802087447",
language = "English",
volume = "49",
pages = "1321--1328",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "7",

}

TY - JOUR

T1 - Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas

T2 - A single centre experience

AU - Uccella, Silvia

AU - Placidi, Claudia

AU - Marchet, Silvia

AU - Cergnul, Massimiliano

AU - Proserpio, Ilaria

AU - Chini, Claudio

AU - Novario, Raffaele

AU - Pinotti, Graziella

AU - Capella, Carlo

PY - 2008/7

Y1 - 2008/7

N2 - Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. The immunohistochemistry-based algorithms for the determination of the cell of origin of DLBCL have been proposed as a practical method to validate and surrogate results obtained by gene expression profiling. We studied 71 patients with primary nodal DLBCL at diagnosis, who received anthracycline-based therapy with or without rituximab. Immunohistochemistry was performed using anti-CD10, Bcl-6, MUM1 and Bcl-2 antibodies in order to assess the ontogenic profile of neoplastic cells and to verify its relation with clinical outcome. Survival data were analysed using an explorative Cox model. The immunohistochemistry-based algorithms for the determination of the cell of origin of DLBCL were not associated with prognosis. By contrast, Bcl-6 expression was associated with a longer lymphoma-free survival while immunoreactivities for MUM1 or Bcl-2 were not significantly related to patient outcome. Bcl-6 expression alone proved to be a prognostic marker in primary nodal DLBCL and seemed to be more reliable to predict clinical outcome in these disorders than the immunohistochemical algorithms for the detection of the germinal centre/non-germinal centre immunophenotype.

AB - Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. The immunohistochemistry-based algorithms for the determination of the cell of origin of DLBCL have been proposed as a practical method to validate and surrogate results obtained by gene expression profiling. We studied 71 patients with primary nodal DLBCL at diagnosis, who received anthracycline-based therapy with or without rituximab. Immunohistochemistry was performed using anti-CD10, Bcl-6, MUM1 and Bcl-2 antibodies in order to assess the ontogenic profile of neoplastic cells and to verify its relation with clinical outcome. Survival data were analysed using an explorative Cox model. The immunohistochemistry-based algorithms for the determination of the cell of origin of DLBCL were not associated with prognosis. By contrast, Bcl-6 expression was associated with a longer lymphoma-free survival while immunoreactivities for MUM1 or Bcl-2 were not significantly related to patient outcome. Bcl-6 expression alone proved to be a prognostic marker in primary nodal DLBCL and seemed to be more reliable to predict clinical outcome in these disorders than the immunohistochemical algorithms for the detection of the germinal centre/non-germinal centre immunophenotype.

KW - Bcl-6

KW - CD10

KW - Diffuse large B-cell lymphoma

KW - Germinal centre phenotype

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=47649109496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47649109496&partnerID=8YFLogxK

U2 - 10.1080/10428190802087447

DO - 10.1080/10428190802087447

M3 - Article

C2 - 18604721

AN - SCOPUS:47649109496

VL - 49

SP - 1321

EP - 1328

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -